Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DR. DATSONS LABS Mar-14 |
MYLAN Dec-18 |
DR. DATSONS LABS/ MYLAN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 126 | 3,554 | - | |
Low | Rs | 31 | 1,956 | - | |
Sales per share (Unadj.) | Rs | 133.0 | 1,635.5 | - | |
Earnings per share (Unadj.) | Rs | 0.2 | 44.4 | - | |
Cash flow per share (Unadj.) | Rs | 6.6 | 350.6 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Dividend yield (eoy) | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 128.8 | 1,769.3 | - | |
Shares outstanding (eoy) | m | 31.66 | 514.50 | - | |
Bonus/Rights/Conversions | FCCB | - | - | ||
Price / Sales ratio | x | 0.6 | 1.7 | 34.9% | |
Avg P/E ratio | x | 516.1 | 62.0 | 831.9% | |
P/CF ratio (eoy) | x | 11.8 | 7.9 | 150.7% | |
Price / Book Value ratio | x | 0.6 | 1.6 | 39.0% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 2,477 | 1,417,614 | 0.2% | |
No. of employees | `000 | NA | 35.0 | 0.0% | |
Total wages/salary | Rs m | 56 | 0 | - | |
Avg. sales/employee | Rs Th | NM | 24,041.6 | - | |
Avg. wages/employee | Rs Th | NM | 0 | - | |
Avg. net profit/employee | Rs Th | NM | 652.8 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 4,211 | 841,456 | 0.5% | |
Other income | Rs m | 79 | 0 | - | |
Total revenues | Rs m | 4,289 | 841,456 | 0.5% | |
Gross profit | Rs m | 569 | 217,738 | 0.3% | |
Depreciation | Rs m | 204 | 157,554 | 0.1% | |
Interest | Rs m | 430 | 40,471 | 1.1% | |
Profit before tax | Rs m | 13 | 19,713 | 0.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | -2 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 6 | -3,136 | -0.2% | |
Profit after tax | Rs m | 5 | 22,849 | 0.0% | |
Gross profit margin | % | 13.5 | 25.9 | 52.2% | |
Effective tax rate | % | 48.0 | -15.9 | -301.9% | |
Net profit margin | % | 0.1 | 2.7 | 4.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 6,852 | 469,868 | 1.5% | |
Current liabilities | Rs m | 6,711 | 342,586 | 2.0% | |
Net working cap to sales | % | 3.3 | 15.1 | 22.1% | |
Current ratio | x | 1.0 | 1.4 | 74.4% | |
Inventory Days | Days | 161 | 84 | 192.5% | |
Debtors Days | Days | 318 | 93 | 341.3% | |
Net fixed assets | Rs m | 3,673 | 163,229 | 2.3% | |
Share capital | Rs m | 317 | 448 | 70.7% | |
Net worth | Rs m | 4,078 | 910,302 | 0.4% | |
Long term debt | Rs m | 1,671 | 982,508 | 0.2% | |
Total assets | Rs m | 12,633 | 2,441,784 | 0.5% | |
Interest coverage | x | 1.0 | 1.5 | 69.2% | |
Debt to equity ratio | x | 0.4 | 1.1 | 38.0% | |
Sales to assets ratio | x | 0.3 | 0.3 | 96.7% | |
Return on assets | % | 3.4 | 2.6 | 132.8% | |
Return on equity | % | 0.1 | 2.5 | 4.7% | |
Return on capital | % | 7.7 | 3.2 | 241.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,345 | 174,855 | 0.8% | |
From Investments | Rs m | -2,256 | -90,381 | 2.5% | |
From Financial Activity | Rs m | -1,200 | -81,458 | 1.5% | |
Net Cashflow | Rs m | -2,111 | 1,449 | -145.7% |
Compare DR. DATSONS LABS With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare DR. DATSONS LABS With: CIPLA WYETH STERLING BIOTECH ALEMBIC PHARMA PROCTER & GAMBLE HEALTH
Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.
Should you bet on this gaming company backed by ace investor Rakesh Jhunjhunwala?
More Views on NewsIn this video, I'll tell you why I am recommending caution in the market at this time.
A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
In this video I'll show you exactly how I go about picking stocks for trading.
100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
More